Overview: Tuberculosis (TB) Antigen Rapid TestIntroduction: The Tuberculosis (TB) Antigen Rapid Test is a diagnostic tool designed to detect TB antigens in sputum, whole blood, or saliva samples, facilitating the screening of tuberculosis. Caused by Mycobacterium tuberculosis, this chronic bacterial infection presents with cough, weight loss, and severe complications like disseminated TB or death if untreated, particularly in high-burden regions or immunocompromised individuals. Per the 2023 World Health Organization guidelines, the test employs immunochromatographic technology, delivering results within 15-20 minutes with high sensitivity and specificity, making it a critical tool for rapid diagnosis in resource-limited settings. This rapid diagnostic falls under bacteriology and targets individuals with respiratory symptoms or risk factors like HIV, addressing the challenge of early detection to guide treatment with isoniazid or rifampicin and interrupt transmission. With morbidity rates elevated due to drug resistance, the test supports public health efforts by enabling early case identification, facilitating contact tracing, and promoting directly observed therapy (DOT). Its multi-sample capability enhances its utility.Other Names: TB Rapid Test.FDA Status: FDA approved, CLIA certified for bacteriology, compliant with 2025 standards.Historical Milestone: Introduced in the 2000s by Alere, this test advanced TB detection, providing a rapid alternative to sputum smear microscopy.Purpose: The test screens for TB antigens to guide tuberculosis diagnosis, assess disease stage, and inform treatment and prevention strategies.Test Parameters: Presence of TB Antigen, detected with high specificity to indicate active infection, typically detectable in sputum or blood within 2-4 weeks of symptom onset.Pretest Condition: No fasting required; patients should avoid food or drink for 30 minutes prior to collection to ensure sample integrity, and they should report cough, weight loss, or recent TB exposure.Specimen: Sputum 5-10 mL, Whole Blood 2-5 mL, Saliva 1-2 mL, collected using sterile containers or EDTA tubes, transported within 24 hours to maintain sample viability.Sample Stability at Room Temperature: 24 hours with proper handling in a cool environment to preserve antigen integrity, ensuring reliable test performance.Sample Stability at Refrigeration: 48 hours at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.Sample Stability at Frozen: Not recommended, as freezing may denature antigens, increasing the risk of false negatives and compromising diagnostic accuracy.Medical History: Patients should provide details on cough, weight loss, night sweats, or prior TB infections, as well as any HIV status or recent contact with TB cases.Consent: Written informed consent is required, detailing the test's purpose, potential risks of untreated infection including death, benefits of early detection, and minimal discomfort from sample collection.Procedural Considerations: The test utilizes an immunochromatographic cassette requiring trained personnel to ensure sterile technique, avoid contamination, and interpret results within 15-20 minutes using provided positive and negative controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store test kits according to manufacturer specifications to ensure reliability.Factors Affecting Result Accuracy: Delays beyond 24 hours, improper storage conditions, cross-contamination with other samples, or early infection before antigen development can affect results. Correlation with sputum smear, culture, or GeneXpert is recommended to confirm findings.Clinical Significance: A positive result indicates TB infection, necessitating multi-drug therapy and public health notification. A negative result may require follow-up testing if symptoms persist, especially if sampled too early.Specialist Consultation: Pulmonologists or infectious disease specialists should be consulted for case management, treatment planning, and coordination with TB control programs.Additional Supporting Tests: Sputum smear, TB culture, or GeneXpert for confirmation.Test Limitations: The test may produce false negatives in early infection or false positives due to cross-reactivity, requiring a comprehensive diagnostic approach that includes microbiological confirmation.References: WHO Guidelines 2023, Journal of Infectious Diseases 2024, Tuberculosis 2025.